PL BioScience secures 7.8 million euros in Series A financing

Aachen-based cell culture solution promotes global growth in the field of cell therapy

Aachen, August 2024 - The Aachen-based company PL BioScience has successfully completed a Series A financing of 7.8 million euros. The fresh capital comes from international investors such as AVANT BIO from New York, LePure Biotech from Shanghai, b.value AG from Dortmund and better ventures from Munich. This investment is intended to support the growth of PL BioScience and expand production capacities.

Expansion of production capacities

With the new financing, PL BioScience plans to expand its production capacities and strengthen its position in the global cell culture markets. The company is known for its innovative cell culture media that drive the development of new therapies in regenerative medicine. PL BioScience specializes in Human Platelet Lysate (HPL), which is derived from donated blood and represents a sustainable alternative to conventional cell culture media.

Support from international investors

The financing round was supported by renowned investors, including AVANT BIO, LePure Biotech, b.value AG and better ventures. These partners bring extensive experience in deep tech, life sciences and health tech. They join existing investors such as Brightlands Venture Partners and TechVision Fonds, who have also renewed their support for PL BioScience.

Bernhard Kugel of TechVision Fonds and Dr. Luc Starmans of Brightlands Venture Partners emphasized the importance of the collaboration with the new partners and the potential PL BioScience offers for the future of cell therapy.

Sustainable cell culture media for regenerative medicine

PL BioScience's HPL technology enables significant advances in cell therapy. The use of HPL provides a reliable and sustainable solution for research and enables a seamless translation of research results to humans. This technology is used in laboratories worldwide and supports the development of innovative cell therapies that are critical for the treatment of diseases such as type 1 diabetes and for wound healing.

Strategic expansion and global demand

Dr. Hatim Hemeda, CEO of PL BioScience, sees the increasing demand for high-quality cell culture media as the driving force behind the company's growth. The increasing number of clinical studies, especially with stem cells, requires reliable and effective growth media. The market potential for HPL culture media is growing worldwide, especially in China, where the demand for imported cell culture media is increasing.

Strong partnerships for global growth

The participation of international investors from Europe, the USA and China strengthens PL BioScience's global presence and accelerates the company's growth strategy. Christian Wilkes, co-founder and CFO of PL BioScience, emphasizes the importance of these partnerships for international expansion.

Peter Kallien of b.value AG sees great potential in PL BioScience and praises the company for its scalable and high-quality cell culture media that meet the requirements of clinical cell culture and support the growth of regenerative medicine.